According to breast cancer subtype, 749 790 (73.9%) were HR-positive and ERBB2-negative, 114 249 (11.3%) were HR-negative and ERBB2-negative, 106 139 (10.5%) were HR-positive and ERBB2-positive, and 44 799 (4.4% were HR-negative and ERBB2-positive. This evidence concerns the gene ERBB2 and breast cancer.